Silexion shares surge 17.07% premarket as company announces attendance at RNAi Therapeutics Summit and plans for SIL204's Phase 2/3 trials.

Silexion Therapeutics surged 17.07% in premarket trading following its announcement of participating in the 7th RNAi-Based Therapeutics Summit as an official partner, where management will present SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes in pancreatic cancer. The company highlighted plans to initiate a Phase 2/3 clinical trial for SIL204 in mid-2026, positioning it as a potential breakthrough in oncology. The summit attendance and strategic partnership with the industry’s premier RNAi forum likely boosted investor confidence in Silexion’s pipeline advancements and visibility. The positive momentum aligns with the company’s focus on innovating treatments for KRAS-driven cancers, a high-unmet-need area, reinforcing optimism ahead of key clinical milestones.